Patient Rating:

4.8 out of 5

60 Patient Ratings
59 Patient Comments

Michael W. Deininger, M.D., Ph.D.

Division Chief, Division of Hematology and Hematologic Malignancies

Patient Rating:

4.8 out of 5

60 Patient Ratings
59 Patient Comments



  • English
  • German
  • Russian

Clinical Details

Phone Number Clinical Office Address
(801) 587-4630
Huntsman Cancer Hospital
Clinic 2C/BMT, Hematology-Benign
1950 Circle of Hope
Salt Lake City, UT 84112
(801) 585-6906
Huntsman Cancer Hospital
Clinic 2C/BMT, Hematology-Malignant
1950 Circle of Hope
Salt Lake City, UT 84112



Michael Deininger, MD, PhD, is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He has extensive experience treating patients with blood cancers. He has a particular interest in chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia. He sees patients at the University of Utah Huntsman Cancer Institute, Clinic 2B.

For questions regarding Dr. Deininger's practice, our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist/New Patient Coordinator at or (801) 587-4630.

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Oncological Sciences - Adjunct Professor
Academic Divisions Hematology/BMT
Cancer Center Programs Experimental Therapeutics

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
My confidence in care provider
Time care provider spent with me
Care provider spoke using clear language
Care provider's effort to include me in decisions
Care provider's concern for questions & worries
Care provider's explanation of condition/problem
Wait time at clinic
Care provider's friendliness and courtesy

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

September 25, 2015

Dr. D is awesome. We have been through some challenging times with how my myeloma has decided to behave. Dr. D has been very thorough in his explain of where we need to go (alway including me in the decision-making process) and moving aggressively on thid disease. His person commitment to keeping me in the loop goes well above the call of duty - including a Friday night phone call from when he was at a social, when he received by results he immediatly called me from that social with positive news. That is the type of relationship that builds / sustains trust and confidence in each other. I am very lucky to have Dr. D as my care provider.

August 28, 2015

we really love having Dr. Deininger as a doctor

August 28, 2015

ALLWAYS recomend Huntsman Hospital to friends .

April 10, 2015

We really appreciate everyone at Huntsman

March 22, 2015

In my opinion, I am lucky to receive care at Huntsman.I have a lot of faith in the medical staff here.

March 20, 2015

dr.deineger has wonderful bedside manner and I feel like he truly cares and understands

February 13, 2015

We would highly recommend the Huntsman

January 16, 2015

I would highly recommend Huntsman and Dr. Deininger

January 12, 2015

Dr Deininger is really a wonderful doctor to work with He makes me feel like I am important and he answers all my questions and concerns. I rave to all my friends about him and tell them that if they get leukemia they need to go to him!

December 11, 2014

really feel they care about me and my situation

November 24, 2014

Not one complaint. Myeloma treatment is not a one size fits all - especially in light of all the emerging (and in many instances research results that somewhat contradict each other). it is important the care provider and patient explore this emerging data some the patient can ultimately make the best decision for their body.

October 26, 2014

I always feel like Dr. Deininger is including me in the decision-making process about my treatment plan. I have asked A LOT of questions, and his patience is outstanding. It is very evident Dr. Deininger not only has a passion for his work, but the importance a care provider has in the holistic approach in treating cancer.

October 21, 2014

De.Deininger is AWESOME!

September 25, 2014

Both Dr. Deininger and PA Sri Tantravani are excellent. I love how they explain any aspect I have questions or concerns about. They make me feel like they care and they have time for me.

August 28, 2014

Given the circumstances, it was a very positive experience.

July 06, 2014


July 01, 2014

Dr. Deininger, the fellow, Sri, the nurse practitioner, Renee, the nurse, Mary, all the lab technicians, MA's, and administrative assistants could not have higher standards.

June 28, 2014

I couldn't be happier with both Dr. Deininger and his assistant Sri Tantravanhi. They certainly make me feel like they have time to answer questions and explain things to me, and they don't talk down to me by over-simplifying. They both have great client relationship skills.

June 19, 2014

I would have liked to spend a bit more time with the Doct, but I guess that will happen once test results are in.

June 19, 2014

Dr. Deininger is an incredible doctor. It is sometimes difficult to explain your symptoms to him using language you both understand, but you finally get there. I can accept this due to his expertise.

June 19, 2014

dr. is very knowledgable and caring. very kind and understanding.

June 16, 2014

Only concern was wait time

June 10, 2014

This is the struggle I am having. I have been throwing around the idea of seeking treatment elsewhere. But I truly believe in Dr.Deineger and his abilities. He is a fabulous doctor, its the fact that I see him so little and the people I am left to deal with if I have questions are not good. The fact that I have to bring these concerns up in a facility that is world renowned and has such a honest, caring philosophy behind it is saddening.

June 09, 2014

Dr. Deininger and all of his staff I would highly recommend as this is a very stressful time in life and they do everything they can to make it as good as possible.

May 15, 2014

I'm so thrilled with my new doctor and his assistant. It's clear they both explain things in as much detail as I need. I love his style (both of them actually). I feel my relationship with them will be very good.

May 05, 2014

We love having Dr. Deininger as a Doctor he makes us feel very comfortable

April 30, 2014

I mentioned the bad experience I had with this bone marrow aspiration. The doctor shook his head and said yea you had a painful experience I know. This seemed rude to me. All I needed was for my doctor to acknowledge it and act a little concerned that I was still in pain. It makes me think they should experience an aspiration so they can relate to the patients more. He did give me good news for which I was very grateful.

April 30, 2014

She did have problems getting me numbed up so this procedure was the most painful of all the aspirations I have had. No necessarily putting all the blame on the PA.

April 24, 2014

I spoke with a fellow and then later the doctor. They were both very knowledgable. Their explanations were crystal clear. They also calmed my fears about my prognosis.

March 27, 2014

I would recommend Dr. Deininger to anyone but not the wait time required to see him.

March 10, 2014

I am hard of hearing & had to rely on my husband in some instances. The Doctor is very soft spoken.

March 04, 2014

very impressed with Dr. Deininger and confident with him as my physician

February 24, 2014

I have the utmost trust in Dr. Deininger and his staff

January 31, 2014

I'm not sure what to expect for my upcoming visit. it's for a bone marrow biopsy. and I'm nervous. I would like to know what I need to do to prepare. I left the exam room with the possibility of having the procedure done that day, but after waiting for blood results I found out that I had to schedule it for another appointment. I made the new appointment and left, not knowing anything about what to expect.

January 16, 2014

I like and prefer them.

January 01, 2014

The care of all who participated in the segments of the appointment was excellent -- caring and considerate and professional. The excellent medical service performed by the doctor for completion of the Bone Marrow Biopsy was particularly appreciated, helping to make the experience only of modest discomfort. Overall, the day's activity with the various aspects (components) of the appointment/visit were quite positive.

December 27, 2013

I could not be more pleased with the care I received from Dr. Deininger.

December 19, 2013

the PA asked what I was having done and who ordered the procedure as she did not have that info- instills a lot of confidence in you! The MD did explain the procedure well

December 14, 2013

I am confident with Huntsman and I think I get the best care possible

December 02, 2013

The Dr. spent time describing my options and how the treatments would affect me. He answered all my family's questions.

November 25, 2013

Dr Deininger is very soft spoken so he was very calming

November 20, 2013

The care takers are very good.they are skilled and experienced.

October 19, 2013

I always feel as though my health problems are a real concern to those who help me at the Huntsman Center

October 04, 2013

no bad ones

October 04, 2013

They all know their job very well and take every care of the patient.

July 24, 2013

Dr. D is an exceptional doc! I am so blessed to have found him!!!

July 17, 2013

They were caring and knowledgeable and friendly.

March 04, 2013

i woud recommend the provider, but NOT in this clinic.

February 04, 2013

The main Dr was great! The ast not so much I feel he didn't really listen & kept asking me the same questions over & over

January 01, 2013

I was so impressed with the time the doctor and intern. spent with me explaining my condition. They genuinely cared for me. This was the first time I had met my doctor and I now completely trust him. I feel he cares about me and my health.

November 30, 2012

I wasn't sure what to expect coming in (though I had spoken with someone who had been there). I was impressed with how thorough everyone was. No one seemed rushed or in a hurry to leave. I was grateful for the information and left feeling much better than when I arrived (about my care going forward).

November 23, 2012

All the doctors I've seen obviously talk with each other and all are on the same page. They are willing to discuss anything and everything on the patients terms. I like and trust all the doctors.

November 18, 2012

The attending MD fellow was very thorough in his examination and explanations as well as the primary physician. They clearly listened to my concerns and were willing to work towards approaches to my medical condition.

October 22, 2012

very pleased with doctor. Due to may hearing difficulties and docotr's softspokeness, I hade to keep asking him to repeat himself. Sorry

October 19, 2012

Dr. Deininger was fabulous! I had such a good experience with him & was so glad that I was able to get an appointment with him. I have lots of confidence with him & am looking forward to the next visit.

October 08, 2012

Excellent care and service thank you

September 28, 2012

Dr Deininger is very easy to talk to and he does explain in terms that are very understandable to me. He makes a person feel as if he is in no hurry and will set there for as long as it takes to answer all my questions. My family and I are very impressed with him.

July 20, 2012

Dr Deininger will be making recommendations after reviewing all my records and biopsy slides. I am confident that the advice for treatment will be well-thought out because of the time he is taking to review everything before making a final decision for t

April 03, 2012

The care providers were great.

Academic Profile

Research Interests

  • Chronic Myeloid Leukemia
  • Myeloproliferative Neoplasms
  • Leukemia Drug Resistance
  • Autologous Stem Cell Transplantation

Board Certification and Academic Information

Academic Departments Internal Medicine - Professor
Oncological Sciences - Adjunct Professor
Academic Divisions Hematology/BMT
Cancer Center Programs Experimental Therapeutics

Academic Office Locations

Academic Office Phone Number Academic Office Address
(801) 581-6363 Huntsman Cancer Institute
2000 Circle of Hope
Salt Lake City, UT 84112

Academic Bio

Michael Deininger is Professor and Chief of Hematology and Hematologic Malignancies in the Department of Internal Medicine and the Huntsman Cancer Institute (HCI) at the University of Utah. He is an HCI investigator and member of the Experimental Therapeutics program. He has extensive experience treating patients with blood cancers, including chronic myeloid leukemia (CML) and myeloproliferative neoplasms, a group of blood cancers related to leukemia.

Dr. Deininger received his MD from the University of Würzburg Medical School, Germany, in 1990. Throughout his studies he was funded by the prestigious German Scholarship Foundation. He subsequently trained in Internal Medicine and Hematology/Oncology. In 1995 he obtained a grant to enroll in the PhD program at Imperial College, London. His thesis work focused on signal transduction and the potential use of imatinib (Gleevec) as molecularly targeted therapy for CML. After returning to Germany he completed a fellowship in stem cell transplantation at the University of Leipzig Medical Center. In 2002 he was recruited to the Division of Hematology and Medical Oncology at Oregon Health & Science University as an Assistant Professor. In 2007 he was promoted to the rank of Associate Professor and became the Head of the Hematologic Malignancies Section at OHSU. In August 2010 Dr. Deininger became the M.M. Wintrobe Professor of Medicine at the University of Utah and was appointed Chief of the Division of Hematology and Hematologic Malignancies. He was also appointed Senior Director for Transdisciplinary Research at Huntsman Cancer Institute.

Dr. Deininger’s scientific focus is leukemia, specifically myeloproliferative neoplasms (MPN) including CML, chronic myelomonocytic leukemia (CMML) and myelofibrosis (MF). As a clinician-scientist with a translational research focus Dr. Deininger is heading an extramurally funded research laboratory that is dedicated to the study of signaling pathways, drug resistance and new molecular therapies in leukemia. Dr. Deininger’s work describing the selective effects of imatinib on CML cells provided the rationale for clinical trials that led to the approval of Gleevec as the first molecularly-based therapy for leukemia. Current work in his lab is focused on understanding the role of the bone marrow microenvironment in leukemia drug resistance, discovering novel therapeutic targets and developing more specific signal transduction inhibitors. Dr. Deininger’s work encompasses more than 200 articles in the peer-reviewed literature, including journals like Cancer Cell, Blood, Journal of Clinical Investigation and the New England Journal of Medicine. He has co-authored more than 10 book chapters, with contributions in leading textbooks such as deVita’s Principles of Oncology. He is a regular speaker at major international scientific meetings, such as the American Society of Hematology and the European Hematology Association and a peer reviewer for journals like Nature Genetics and Cancer Cell. His honors include the Alexandra Kefalides Prize for Leukemia Research, membership on the Editorial Board of Blood (the leading journal in Hematology) and Thompson Reuters Highly Cited Researcher award in 2014 and 2015. Dr. Deininger serves as the vice-Chair for NCCN CML panel and is a member of the NCCN MPN panel.


Education History

Type School Degree
Fellowship University of Leipzig, Department of Hematology
Clinical Fellow
Doctoral Training Imperial College London
Research Fellow Hammersmith Hospital, Department of Haematology
Research Fellow
Residency Institute of Medical Oncology and Haematology, Nürnberg General Hospital
Internship Katholische Stiftung Marienhospital Aachen
Professional Medical University of Würzburg
Doctoral Training University of Regensburg


Selected Provider Publications

Journal Article

  1. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S (2015). The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood, 126(13), 1551-4.
  2. Davare MA, Vellore NA, Wagner JP, Eide CA, Goodman JR, Drilon A, Deininger MW, OHare T, Druker BJ (2015). Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors. Proc Natl Acad Sci U S A, 112(39), E5381-90.
  3. Eiring AM, Khorashad JS, Anderson DJ, Yu F, Redwine HM, Mason CC, Reynolds KR, Clair PM, Gantz KC, Zhang TY, Pomicter AD, Kraft IL, Bowler AD, Johnson K, Partlin MM, OHare T, Deininger MW (2015). beta-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.LID - 10.1038/leu.2015.196 [doi]. (Epub ahead of print) Leukemia.
  4. Deininger MW (2015). Diagnosing and managing advanced chronic myeloid leukemia. Am Soc Clin Oncol Educ Book, 35, e381-8.
  5. Pomicter AD, Eiring AM, Senina AV, Zabriskie MS, Marvin JE, Prchal JT, OHare T, Deininger MW (2015). Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm. Exp Hematol, 43(7), 537-45.e1-11.
  6. Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA (2015). Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma, 56(7), 1938-48.
  7. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Raza A, Vaddi K, Sun W, Peng W, Sandor V, Kantarjian H (2015). Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica, 100(4), 479-88.
  8. Zabriskie MS, Vellore NA, Gantz KC, Deininger MW, OHare T (2015). Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. Leukemia, 29(9), 1939-42.
  9. Woessner DW, Eiring AM, Bruno BJ, Zabriskie MS, Reynolds KR, Miller GD, OHare T, Deininger MW, Lim CS (2015). A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia. Leukemia, 29(8), 1668-75.
  10. Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, OHare T, Deininger MW (2015). shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance. Blood, 125(11), 1772-81.
  11. Yoda A, Adelmant G, Tamburini J, Chapuy B, Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, Liu H, Tivey T, Christie AL, Elpek KG, Card J, Gritsman K, Gotlib J, Deininger MW, Makishima H, Turley SJ, Javidi-Sharifi N, Maciejewski JP, Jaiswal S, Ebert BL, Rodig SJ, Tyner JW, Marto JA, Weinstock DM, Lane AA (2015). Mutations in G protein beta subunits promote transformation and kinase inhibitor resistance. Nat Med, 21(1), 71-5.
  12. Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, OHare T, Gunning PT, Deininger MW (2015). Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia, 29(3), 586-97.
  13. OBrien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, Curtin P, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H (2014). Chronic myelogenous leukemia, version 1.2015. J Natl Compr Canc Netw, 12(11), 1590-610.
  14. Eiring AM, Deininger MW (2014). Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol, 15(9), 461.
  15. Agarwal AAUID- ORCID httporcidorg0000-0002-8319-6162, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, OHare T, Roberts JM, Druker BJ, Deininger MW (2014). BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood, 124(22), 3260-73.
  16. Tantravahi SK, Salama ME, Deininger MN (2014). Aggressive systemic mastocytosis mimicking lymphoma: description of an unusual presentation and review of the literature on current management strategies. Leuk Lymphoma, 55(12), 2963-6.
  17. Deininger M (2014). The current status of ponatinib in the treatment of chronic myeloid leukemia. Clin Adv Hematol Oncol, 12(5), 329-31.
  18. Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI (2014). Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database. J Natl Compr Canc Netw, 12(8), 1113-21.
  19. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, Khoury HJ, Larson RA, Konopleva M, Cortes JE, Kantarjian H, Jabbour EJ, Kornblau SM, Lipton JH, Rea D, Stenke L, Barbany G, Lange T, Hernandez-Boluda JC, Ossenkoppele GJ, Press RD, Chuah C, Goldberg SL, Wetzler M, Mahon FX, Etienne G, Baccarani M, Soverini S, Rosti G, Rousselot P, Friedman R, Deininger M, Reynolds KR, Heaton WL, Eiring AM, Pomicter AD, Khorashad JS, Kelley TW, Baron R, Druker BJ, Deininger MW, OHare T (2014). BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell, 26(3), 428-42.
  20. Jabbour E, Ottmann OG, Deininger M, Hochhaus A (2014). Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica, 99(1), 7-18.
  21. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C (2014). Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica, 99(2), 292-8.
  22. Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, Muller MC, Radich JP, Shah NP (2014). Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res, 38(1), 10-20.
  23. Deininger MW, Kopecky KJ, Radich JP, Kamel-Reid S, Stock W, Paietta E, Emanuel PD, Tallman M, Wadleigh M, Larson RA, Lipton JH, Slovak ML, Appelbaum FR, Druker BJ (2014). Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol, 164(2), 223-32.
  24. OBrien S, Radich JP, Abboud CN, Akhtari M, Altman JK, Berman E, DeAngelo DJ, Deininger M, Devine S, Fathi AT, Gotlib J, Jagasia M, Kropf P, Moore JO, Pallera A, Pinilla-Ibarz J, Reddy VV, Shah NP, Smith BD, Snyder DS, Wetzler M, Gregory K, Sundar H (2013). Chronic Myelogenous Leukemia, Version 1.2014. J Natl Compr Canc Netw, 11(11), 1327-40.
  25. Khorashad JS, Kelley TW, Szankasi P, Mason CC, Soverini S, Adrian LT, Eide CA, Zabriskie MS, Lange T, Estrada JC, Pomicter AD, Eiring AM, Kraft IL, Anderson DJ, Gu Z, Alikian M, Reid AG, Foroni L, Marin D, Druker BJ, OHare T, Deininger MW (2013). BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood, 121(3), 489-98.
  26. OHare T, Eide CA, Agarwal A, Adrian LT, Zabriskie MS, Mackenzie RJ, Latocha DH, Johnson KJ, You H, Luo J, Riddle SM, Marks BD, Vogel KW, Koop DR, Apgar J, Tyner JW, Deininger MW, Druker BJ (2013). Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis. Cancer Res, 73(11), 3356-70.
  27. Corbin AS, OHare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW (2013). KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors. Cancer Res, 73(18), 5775-86.
  28. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM (2013). Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica, 98(12), 1865-71.
  29. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H (2013). A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med, 369(19), 1783-96.
  30. Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW (2012). Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood, 120(13), 2658-68.
  31. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, OHare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012). Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med, 367(22), 2075-88.
  32. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, OHare T, Druker BJ, Deininger MW (2012). Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia, 26(5), 1140-3.
  33. Deininger M (2011). Hematology: curing CML with imatinib--a dream come true? Nat Rev Clin Oncol, 8(3), 127-8.
  34. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, OHare T, Druker BJ, Bagby GC, Deininger MW (2011). TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood, 118(24), 6392-8.
  35. Tyner JW, Bumm TG, Deininger J, Wood L, Aichberger KJ, Loriaux MM, Druker BJ, Burns CJ, Fantino E, Deininger MW (2010). CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 115(25), 5232-40.
  36. Sherbenou DW, Hantschel O, Kaupe I, Willis S, Bumm T, Turaga LP, Lange T, Dao KH, Press RD, Druker BJ, Superti-Furga G, Deininger MW (2010). BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood, 116(17), 3278-85.
  37. McWeeney SK, Pemberton LC, Loriaux MM, Vartanian K, Willis SG, Yochum G, Wilmot B, Turpaz Y, Pillai R, Druker BJ, Snead JL, MacPartlin M, OBrien SG, Melo JV, Lange T, Harrington CA, Deininger MW (2010). A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood, 115(2), 315-25.


  1. Moslehi JJ, Deininger M (2015). Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.LID - JCO.2015.62.4718 [pii]. [Review]. J Clin Oncol.
  2. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Muller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saussele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. [Review]. Blood, 122(6), 872-84.
  3. OHare T, Zabriskie MS, Eiring AM, Deininger MW (2012). Pushing the limits of targeted therapy in chronic myeloid leukaemia. [Review]. Nat Rev Cancer, 12(8), 513-26.


  1. Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, OHare T, Goldman JM (2013). What challenges remain in chronic myeloid leukemia research? Haematologica, 98(8), 1168-72.
  2. Khorashad JS, Deininger MW, OHare T (2013). New concepts for CML clonality. Oncotarget, 4(1), 7-8.


  1. Tantravahi SK, Schumacher J, Burt RW, Kelley TW, Deininger MW (2014). Systemic mastocytosis in a patient with Cowden syndrome [Letter to the editor]. Am J Hematol, 89(12), 1154.


  1. Andersen EF, Salama ME, Sederberg MC, Toydemir RM, Kovacsovics TJ, Parker CJ, Rodgers GM, Shami PJ, Deininger MW, South ST (2015). Evaluating the Clinical Utility of Peripheral Blood Samples for Molecular Evaluation of MDS by SNP-A [Abstract]. Leukemia Research, 39(S1), S72.

Clinical Trials

Video & News